All In MedTech

Device Trial Radar · NCT02009644

Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

A Phase II Clinical Study of the Safety and Performance of the Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

158

Actual

Start

Nov 23, 2013

Primary completion

Mar 20, 2017

Study completion Jan 22, 2026

Sponsor

Lead sponsor
Bolton MedicalNot on our public-company list
Sponsor type
Industry
First posted
Dec 12, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).

Conditions

  • Abdominal Aortic Aneurysm (AAA)

Interventions

  • Subjects who receive the Treovance stent-graftDevice

    Eligible subjects will be implanted with the Treovance Stent-Graft

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EfficacyTime frame: 12 months
  2. Primary SafetyTime frame: 30 days

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama-Birmingham

    Birmingham, Alabama

  • Arizona Heart Institute

    Phoenix, Arizona

  • Danbury Hospital

    Danbury, Connecticut

26 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.